|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
16.70(B) |
Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
52
Week Range: |
$76.22 - $99 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 811 |
Guru Rank Value : 0.9 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
139,229 |
182,993 |
316,353 |
613,922 |
Total Sell Value |
$12,316,080 |
$16,513,389 |
$28,948,007 |
$58,289,822 |
Total People Sold |
5 |
5 |
6 |
8 |
Total Sell Transactions |
11 |
15 |
24 |
55 |
End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-02-28 |
4 |
OE |
$12.99 |
$64,950 |
I/I |
5,000 |
18,545 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2013-02-27 |
4 |
S |
$56.90 |
$455,186 |
D/D |
(8,000) |
46,200 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2013-02-27 |
4 |
OE |
$14.39 |
$125,884 |
D/D |
8,000 |
54,200 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-02-27 |
4 |
S |
$56.46 |
$84,683 |
D/D |
(1,500) |
120,401 |
|
- |
|
Lewis Alan |
Director |
|
2013-02-27 |
4 |
S |
$56.57 |
$1,272,762 |
D/D |
(22,500) |
15,900 |
|
- |
|
Lewis Alan |
Director |
|
2013-02-27 |
4 |
OE |
$14.39 |
$558,675 |
D/D |
22,500 |
38,400 |
|
- |
|
Lapalme Pierre |
Director |
|
2013-02-26 |
4 |
S |
$55.34 |
$1,654,798 |
D/D |
(29,900) |
24,650 |
|
- |
|
Lapalme Pierre |
Director |
|
2013-02-26 |
4 |
OE |
$8.47 |
$306,853 |
D/D |
29,900 |
54,550 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2013-02-22 |
4 |
AS |
$55.00 |
$171,344 |
D/D |
(3,103) |
23,245 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2013-02-22 |
4 |
OE |
$14.39 |
$72,412 |
D/D |
3,103 |
26,348 |
|
- |
|
Meier Richard A |
Director |
|
2013-02-19 |
4 |
AS |
$57.50 |
$287,500 |
D/D |
(5,000) |
18,650 |
|
- |
|
Meier Richard A |
Director |
|
2013-02-19 |
4 |
OE |
$16.92 |
$84,600 |
D/D |
5,000 |
23,650 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-02-04 |
4 |
AS |
$55.77 |
$111,532 |
D/D |
(2,000) |
153,691 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-02-04 |
4 |
OE |
$12.99 |
$25,980 |
D/D |
2,000 |
155,691 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-01-23 |
4 |
AS |
$55.22 |
$220,880 |
D/D |
(4,000) |
153,691 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2013-01-22 |
4 |
GA |
$0.00 |
$0 |
I/I |
2,675 |
8,238 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2013-01-22 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,675 |
52,350 |
|
- |
|
Meier Richard A |
Director |
|
2013-01-22 |
4/A |
AS |
$55.00 |
$275,000 |
D/D |
(5,000) |
18,650 |
|
- |
|
Meier Richard A |
Director |
|
2013-01-22 |
4/A |
OE |
$16.92 |
$84,600 |
D/D |
5,000 |
23,650 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-01-22 |
4 |
AS |
$55.00 |
$550,000 |
D/D |
(10,000) |
157,691 |
|
- |
|
Ajer Jeffrey Robert |
SVP, Chief Commercial Of |
|
2013-01-22 |
4 |
AS |
$55.00 |
$165,000 |
D/D |
(3,000) |
10,570 |
|
- |
|
Ajer Jeffrey Robert |
SVP, Chief Commercial Of |
|
2013-01-22 |
4 |
OE |
$21.51 |
$64,530 |
D/D |
3,000 |
13,570 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2013-01-22 |
4 |
AS |
$54.81 |
$2,570,702 |
D/D |
(46,749) |
25,646 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2013-01-22 |
4 |
OE |
$14.39 |
$1,752,561 |
D/D |
46,749 |
72,395 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2013-01-22 |
4 |
AS |
$55.00 |
$1,076,625 |
D/D |
(19,575) |
100,413 |
|
- |
|
1335 Records found
|
|
Page 15 of 54 |
|
|